Optical Disorders Drugs Market by Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs), Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema), End-User - Global Forecast 2024-2030

Optical Disorders Drugs Market by Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs), Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema), End-User - Global Forecast 2024-2030


The Optical Disorders Drugs Market size was estimated at USD 3.14 billion in 2023 and expected to reach USD 3.56 billion in 2024, at a CAGR 13.29% to reach USD 7.54 billion by 2030.

Global Optical Disorders Drugs Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Optical Disorders Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Optical Disorders Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Optical Disorders Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Kiora Pharmaceuticals, Inc., Merck & Co., Inc., Nicox SA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Optical Disorders Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Prescription Type
Over-The-Counter Drugs
Prescription Ophthalmic Drugs
Therapeutics
Age-Related Macular Degeneration
Conjunctivitis
Diabetic Macular Edema
Diabetic Retinopathy
Dry Eye
Eye Cancer
Geographic Atrophy
Glaucoma
Keratitis
Lens Opacification & Intraocular Lens
Retinal Vein Occlusion
End-User
Diagnostic Centers
Eye Clinics
Hospitals
Patient
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Optical Disorders Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Optical Disorders Drugs Market?
3. What are the technology trends and regulatory frameworks in the Optical Disorders Drugs Market?
4. What is the market share of the leading vendors in the Optical Disorders Drugs Market?
5. Which modes and strategic moves are suitable for entering the Optical Disorders Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Optical Disorders Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand owing to increased digital exposure and unhealthy lifestyle
5.1.1.2. Prevalence of eye related disorders in geriatric population
5.1.1.3. Rise in the use of contact lenses and related disorders
5.1.2. Restraints
5.1.2.1. High treatment cost and lack of health insurance in developing economies
5.1.3. Opportunities
5.1.3.1. Technological advancements in optic drugs
5.1.3.2. Rising prevalence of glaucoma and an increase in healthcare expenditure
5.1.4. Challenges
5.1.4.1. Adverse health impacts of drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Optical Disorders Drugs Market, by Prescription Type
6.1. Introduction
6.2. Over-The-Counter Drugs
6.3. Prescription Ophthalmic Drugs
7. Optical Disorders Drugs Market, by Therapeutics
7.1. Introduction
7.2. Age-Related Macular Degeneration
7.3. Conjunctivitis
7.4. Diabetic Macular Edema
7.5. Diabetic Retinopathy
7.6. Dry Eye
7.7. Eye Cancer
7.8. Geographic Atrophy
7.9. Glaucoma
7.10. Keratitis
7.11. Lens Opacification & Intraocular Lens
7.12. Retinal Vein Occlusion
8. Optical Disorders Drugs Market, by End-User
8.1. Introduction
8.2. Diagnostic Centers
8.3. Eye Clinics
8.4. Hospitals
8.5. Patient
9. Americas Optical Disorders Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Optical Disorders Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Optical Disorders Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Bausch & Lomb Incorporated
13.1.3. Bayer AG
13.1.4. Cipla Limited
13.1.5. F. Hoffmann-La Roche Ltd
13.1.6. GlaxoSmithKline PLC
13.1.7. Kiora Pharmaceuticals, Inc.
13.1.8. Merck & Co., Inc.
13.1.9. Nicox SA
13.1.10. Novartis AG
13.1.11. Pfizer, Inc.
13.1.12. Regeneron Pharmaceuticals Inc
13.1.13. Santen Pharmaceutical Co., Ltd.
13.1.14. Senju Pharmaceutical Co., Ltd.
13.1.15. Sun Pharmaceutical Industries Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. OPTICAL DISORDERS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. OPTICAL DISORDERS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. OPTICAL DISORDERS DRUGS MARKET DYNAMICS
FIGURE 7. OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
FIGURE 8. OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
FIGURE 10. OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings